TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma.

MLA

Hongbo Wang, et al. “TPD52L2 as a Potential Prognostic and Immunotherapy Biomarker in Clear Cell Renal Cell Carcinoma.” Frontiers in Oncology, Dec. 2023, pp. 1–18. EBSCOhost, https://doi.org/10.3389/fonc.2023.1210910.

APA

Hongbo Wang, Zhendong Liu, Yuelin Du, Xingbo Cheng, Shanjun Gao, Yanzheng Gao, & Panfeng Shang. (2023). TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma. Frontiers in Oncology, 1–18. https://doi.org/10.3389/fonc.2023.1210910

Chicago

Hongbo Wang, Zhendong Liu, Yuelin Du, Xingbo Cheng, Shanjun Gao, Yanzheng Gao, and Panfeng Shang. 2023. “TPD52L2 as a Potential Prognostic and Immunotherapy Biomarker in Clear Cell Renal Cell Carcinoma.” Frontiers in Oncology, December, 1–18. doi:10.3389/fonc.2023.1210910.